Toll Free: 1-888-928-9744

Chronic Pain - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 382 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Pain - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Chronic Pain - Pipeline Review, H1 2016', provides an overview of the Chronic Pain pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Pain
- The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects
- The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Pain

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 Introduction 6 Chronic Pain Overview 7 Therapeutics Development 8 Chronic Pain - Therapeutics under Development by Companies 10 Chronic Pain - Therapeutics under Investigation by Universities/Institutes 17 Chronic Pain - Pipeline Products Glance 18 Chronic Pain - Products under Development by Companies 22 Chronic Pain - Products under Investigation by Universities/Institutes 30 Chronic Pain - Companies Involved in Therapeutics Development 31 Chronic Pain - Therapeutics Assessment 97 Drug Profiles 114 Chronic Pain - Recent Pipeline Updates 296 Chronic Pain - Dormant Projects 348 Chronic Pain - Discontinued Products 357 Chronic Pain - Product Development Milestones 360 Appendix 366
List of Tables
Number of Products under Development for Chronic Pain, H1 2016 23 Number of Products under Development for Chronic Pain - Comparative Analysis, H1 2016 24 Number of Products under Development by Companies, H1 2016 26 Number of Products under Development by Companies, H1 2016 (Contd..1) 27 Number of Products under Development by Companies, H1 2016 (Contd..2) 28 Number of Products under Development by Companies, H1 2016 (Contd..3) 29 Number of Products under Development by Companies, H1 2016 (Contd..4) 30 Number of Products under Development by Companies, H1 2016 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H1 2016 32 Comparative Analysis by Late Stage Development, H1 2016 33 Comparative Analysis by Clinical Stage Development, H1 2016 34 Comparative Analysis by Early Stage Development, H1 2016 35 Comparative Analysis by Unknown Stage Development, H1 2016 36 Products under Development by Companies, H1 2016 37 Products under Development by Companies, H1 2016 (Contd..1) 38 Products under Development by Companies, H1 2016 (Contd..2) 39 Products under Development by Companies, H1 2016 (Contd..3) 40 Products under Development by Companies, H1 2016 (Contd..4) 41 Products under Development by Companies, H1 2016 (Contd..5) 42 Products under Development by Companies, H1 2016 (Contd..6) 43 Products under Development by Companies, H1 2016 (Contd..7) 44 Products under Investigation by Universities/Institutes, H1 2016 45 Chronic Pain - Pipeline by AbbVie Inc., H1 2016 46 Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H1 2016 47 Chronic Pain - Pipeline by Adynxx, Inc., H1 2016 48 Chronic Pain - Pipeline by Allergan Plc, H1 2016 49 Chronic Pain - Pipeline by Amorsa Therapeutics Inc., H1 2016 50 Chronic Pain - Pipeline by arGEN-X BV, H1 2016 51 Chronic Pain - Pipeline by AskAt Inc., H1 2016 52 Chronic Pain - Pipeline by Astellas Pharma Inc., H1 2016 53 Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H1 2016 54 Chronic Pain - Pipeline by AstraZeneca Plc, H1 2016 55 Chronic Pain - Pipeline by Axsome Therapeutics, Inc., H1 2016 56 Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2016 57 Chronic Pain - Pipeline by Biogen, Inc., H1 2016 58 Chronic Pain - Pipeline by Bionomics Limited, H1 2016 59 Chronic Pain - Pipeline by Camurus AB, H1 2016 60 Chronic Pain - Pipeline by Cara Therapeutics, Inc., H1 2016 61 Chronic Pain - Pipeline by ChironWells GmbH, H1 2016 62 Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H1 2016 63 Chronic Pain - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2016 64 Chronic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016 65 Chronic Pain - Pipeline by Cyclenium Pharma, Inc., H1 2016 66 Chronic Pain - Pipeline by Cytogel Pharma, LLC, H1 2016 67 Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 68 Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 69 Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 70 Chronic Pain - Pipeline by Echo Pharmaceuticals B.V., H1 2016 71 Chronic Pain - Pipeline by Egalet Corporation, H1 2016 72 Chronic Pain - Pipeline by Eli Lilly and Company, H1 2016 73 Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H1 2016 74 Chronic Pain - Pipeline by Ensysce Biosciences Inc., H1 2016 75 Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 76 Chronic Pain - Pipeline by Grunenthal GmbH, H1 2016 77 Chronic Pain - Pipeline by Heron Therapeutics, Inc., H1 2016 78 Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H1 2016 79 Chronic Pain - Pipeline by Johnson & Johnson, H1 2016 80 Chronic Pain - Pipeline by Kareus Therapeutics, SA, H1 2016 81 Chronic Pain - Pipeline by Kineta, Inc., H1 2016 82 Chronic Pain - Pipeline by Kymab Limited, H1 2016 83 Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 84 Chronic Pain - Pipeline by Lohocla Research Corporation, H1 2016 85 Chronic Pain - Pipeline by Lpath, Inc., H1 2016 86 Chronic Pain - Pipeline by Merck & Co., Inc., H1 2016 87 Chronic Pain - Pipeline by Mertiva AB, H1 2016 88 Chronic Pain - Pipeline by Moberg Pharma AB, H1 2016 89 Chronic Pain - Pipeline by Mundipharma International Ltd, H1 2016 90 Chronic Pain - Pipeline by Nanomerics Ltd, H1 2016 91 Chronic Pain - Pipeline by Nektar Therapeutics, H1 2016 92 Chronic Pain - Pipeline by Neura Therapeutik, LLC, H1 2016 93 Chronic Pain - Pipeline by Orion Oyj, H1 2016 94 Chronic Pain - Pipeline by Pacira Pharmaceuticals, Inc., H1 2016 95 Chronic Pain - Pipeline by Pain Therapeutics, Inc., H1 2016 96 Chronic Pain - Pipeline by PeriphaGen, Inc., H1 2016 97 Chronic Pain - Pipeline by Pfizer Inc., H1 2016 98 Chronic Pain - Pipeline by Phosphagenics Limited, H1 2016 99 Chronic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H1 2016 100 Chronic Pain - Pipeline by Purdue Pharma L.P., H1 2016 101 Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H1 2016 102 Chronic Pain - Pipeline by Ribomic Inc., H1 2016 103 Chronic Pain - Pipeline by Sea4Us, H1 2016 104 Chronic Pain - Pipeline by Shulov Innovative Science Ltd., H1 2016 105 Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H1 2016 106 Chronic Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 107 Chronic Pain - Pipeline by Therapix Biosciences Ltd, H1 2016 108 Chronic Pain - Pipeline by Trevena, Inc., H1 2016 109 Chronic Pain - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 110 Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 111 Assessment by Monotherapy Products, H1 2016 112 Assessment by Combination Products, H1 2016 113 Number of Products by Stage and Target, H1 2016 115 Number of Products by Stage and Mechanism of Action, H1 2016 121 Number of Products by Stage and Route of Administration, H1 2016 126 Number of Products by Stage and Molecule Type, H1 2016 128 Chronic Pain Therapeutics - Recent Pipeline Updates, H1 2016 311 Chronic Pain - Dormant Projects, H1 2016 363 Chronic Pain - Dormant Projects (Contd..1), H1 2016 364 Chronic Pain - Dormant Projects (Contd..2), H1 2016 365 Chronic Pain - Dormant Projects (Contd..3), H1 2016 366 Chronic Pain - Dormant Projects (Contd..4), H1 2016 367 Chronic Pain - Dormant Projects (Contd..5), H1 2016 368 Chronic Pain - Dormant Projects (Contd..6), H1 2016 369 Chronic Pain - Dormant Projects (Contd..7), H1 2016 370 Chronic Pain - Dormant Projects (Contd..8), H1 2016 371 Chronic Pain - Discontinued Products, H1 2016 372 Chronic Pain - Discontinued Products (Contd..1), H1 2016 373 Chronic Pain - Discontinued Products (Contd..2), H1 2016 374


List of Figures
Number of Products under Development for Chronic Pain, H1 2016 23 Number of Products under Development for Chronic Pain - Comparative Analysis, H1 2016 24 Number of Products under Development by Companies, H1 2016 25 Number of Products under Investigation by Universities/Institutes, H1 2016 32 Comparative Analysis by Late Stage Development, H1 2016 33 Comparative Analysis by Clinical Stage Development, H1 2016 34 Comparative Analysis by Early Stage Products, H1 2016 35 Assessment by Monotherapy Products, H1 2016 112 Assessment by Combination Products, H1 2016 113 Number of Products by Top 10 Targets, H1 2016 114 Number of Products by Stage and Top 10 Targets, H1 2016 114 Number of Products by Top 10 Mechanism of Actions, H1 2016 120 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 120 Number of Products by Top 10 Routes of Administration, H1 2016 125 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 125 Number of Products by Top 10 Molecule Types, H1 2016 127 Number of Products by Stage and Top 10 Molecule Types, H1 2016 127

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify